Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Discovery could lead to improved early detection, prevention strategies for sudden cardiac death

Discovery could lead to improved early detection, prevention strategies for sudden cardiac death

FDA grants full approval of SYNRIBO for injection

FDA grants full approval of SYNRIBO for injection

Researchers discover pre-leukemic stem cell that triggers relapse in patients with AML

Researchers discover pre-leukemic stem cell that triggers relapse in patients with AML

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

Ligand Pharmaceuticals' total revenues for Q4 2013 increase 8% to $14.7 million

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

FDA grants Breakthrough Therapy designation to GSK's Promacta/Revolade for treatment of cytopenias

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

CTI announces initiation of pacritinib Phase 2 trial in AML patients with FLT3 mutations

Researchers reveal how genetic susceptibility plays large role in cancer risk

Researchers reveal how genetic susceptibility plays large role in cancer risk

Researchers find that 20% of women with ovarian cancer had inherited mutations in gene pathway

Researchers find that 20% of women with ovarian cancer had inherited mutations in gene pathway

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Going barefoot contributes to hookworm infections

Going barefoot contributes to hookworm infections

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

New drug combination proves effective in treatment of hepatitis C

New drug combination proves effective in treatment of hepatitis C

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Emmaus completes all patient visits for Phase 3 trial of L-glutamine for treatment of sickle cell disease

Erythropoietin may promote cancer cell proliferation and survival

Erythropoietin may promote cancer cell proliferation and survival

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.